MAPT and Alzheimer disease: In addition, the clinical diagnosis of AD often requires cognitive assessments, cranial MRI, and blood tests, as well as biomarkers from positron emission tomography (PET) and cerebrospinal fluid (CSF), such as Aβ42, total tau, and phosphorylated-tau [59].